Abstract:Our previous study demonstrated that the mammalian target of rapamycin complex 1 (mTORC1) pathway is activated in peritoneal fibrosis under high glucose condition. This study aimed to investigate whether valsartan inhibits high glucose-induced peritoneal fibrosis via decreasing the activity of the mTORC1 pathway. We used high glucose peritoneal dialysis solution in a mouse peritoneal dialysis model to induce peritoneal fibrosis in vivo and high glucose in human peritoneal mesothelial cells (HPMCs) to stimulate extracellular matrix accumulation in vitro. After injections of peritoneal dialysis solution containing 4.25% glucose for four weeks, mice showed typical features of peritoneal fibrosis, including markedly increased peritoneal thickness, excessive matrix deposition, increased peritoneal permeability, and higher expression of extracellular matrix proteins, such as α-smooth muscle actin (α-SMA) and collagen I. Oral gavage of valsartan significantly ameliorated these pathological changes at both week 6 and week 8. These effects of valsartan were closely correlated with a decrease in the activation of the mTORC1 signal, which was mediated by the downregulation of the protein expression of phosphorylated (p)-mTOR, p-eukaryotic initiation factor 4E-binding protein 1, and p-p70 S6 kinase 1. Further research showed that the protein expression of mTORC1 signal was positively correlated with the expression of both α-SMA and collagen I in the peritoneum. In vitro, high glucose increased the protein expression of α-SMA and collagen I in a dose-dependent manner, while valsartan significantly inhibited high glucose-induced extracellular matrix accumulation in HPMCs. The effect was also accompanied by a decrease in the activation of the mTORC1 signal. Furthermore, the mTOR agonist MHY1485 reversed the downregulation of extracellular matrix components in HPMCs, even in the presence of valsartan. We conclude that valsartan exerts a protective effect against high glucose-induced peritoneal fibrosis via suppressing the activity of the mTORC1 pathway.Impact statementOur study provided new insight into the mechanism underlying the preservation of the peritoneum by valsartan. The results demonstrated that the mice receiving chronic high glucose (HG) peritoneal dialysis solution infusion showed a typical feature of peritoneal fibrosis (PF), as well as higher expression of α-smooth muscle actin (α-SMA) and collagen I. In vitro, HG increased the protein expression of α-SMA and collagen I in a dose-dependent manner, while valsartan significantly ameliorated these pathological changes. Interestingly, there was a parallel decrease in the activity of mammalian target of rapamycin complex 1 (mTORC1) and the protein expression levels of α-SMA and collagen I upon treatment with valsartan in vivo and in vitro. Moreover, the mTOR agonist MHY1485 reversed the downregulation of α-SMA and collagen I in vitro, even in the presence of valsartan. Altogether, our findings reported for the first time that valsartan exerts a protective effect against HG-induced PF by inhibiting the activity of the mTORC1 pathway.

Valsartan Attenuated Oxidative Stress, Decreased MCP-1 and TGF-β1 Expression in Glomerular Mesangial and Epithelial Cells Induced by High-Glucose Levels.

Protective Effect of Losartan on Endothelial Cells Exposed to High Glucose Levels in Vitro

Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury

Inhibitory Effects of Rosiglitazone on the Synthesis of Reactive Oxygen Species and the Expression of Monocyte Ehemoattractant Protein 1 in Rat Mesangial Cells Cultured in High Glucose

TNF-? and IL-1? Promote Renal Podocyte Injury in T2DM Rats by Decreasing Glomerular VEGF/eNOS Expression Levels and Altering Hemodynamic Parameters

Valsartan Ameliorates High Glucose-Induced Peritoneal FIbrosis by Blocking Mtorc1 Signaling.

Effect of Valsantan on Mesangial Cells under High Glucose Concentration

Effect of valsartan on expression of receptor for advanced glycation end-products in renal tissues of diabetic rats

[Losartan Inhibits High Glucose-Induced CTGF Expression Via ERK1/2 MAPK Pathways in Mouse Mesangial Cells].

High Glucose Induces Renal Mesangial Cell Proliferation and Fibronectin Expression Through JNK/NF-κB/NADPH Oxidase/ros Pathway, Which is Inhibited by Resveratrol

[Effects of Valsartan on the Renal Vascular Endothelial Growth Factor and Its Receptor Flk-1 of Diabetic Rats].

Effect of Losartan on Oxidative Stress in Patients with Diabetic Nephropathy

Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment

Angiopoietin-like protein 3 deficiency combined with valsartan administration protects better against podocyte damage in streptozotocin-induced diabetic nephropathy mice

A Low-Dose Combination of Valsartan and Low Molecular Weight Heparin Better Improved Glomerular Permeability Than Did High-Dose Monotherapy in Rats with Diabetic Nephropathy.

The Attenuation of Moutan Cortex on Oxidative Stress for Renal Injury in AGEs-induced Mesangial Cell Dysfunction and Streptozotocin-Induced Diabetic Nephropathy Rats.

Effect of High Glucose, Angiotensin II and Receptor Antagonist Losartan on the Expression of Connective Tissue Growth Factor in Cultured Mesangial Cells.

Active Vitamin D and Vitamin D Receptor Help Prevent High Glucose Induced Oxidative Stress of Renal Tubular Cells via AKT/UCP2 Signaling Pathway

Effect of Irbesartan on Oxidative Stress and Serum Inflammatory Factors in Renal Tissues of Type 2 Diabetic Rats.

Protective effect of valsartan on the podocytes of diabetic rats

Protective effect of Valsartan on renal function of rats with diabetes mellitus